Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

PARP inhibitors (PARPi), such as Olaparib, have shown promising results in high-grade serous (HGS) epithelial ovarian cancer (EOC) treatment. PARPi sensitivity has been mainly associated with homologous recombination (HR) deficiency, but clinical trials have shown that predicting actual patient resp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Fleury, Hubert, Carmona, Euridice, Morin, Vincent G., Meunier, Liliane, Masson, Jean-Yves, Tonin, Patricia N., Provencher, Diane, Mes-Masson, Anne-Marie
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5522225/
https://ncbi.nlm.nih.gov/pubmed/27374179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10308
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados